Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

Cardio-oncology is a rapidly developing field which seeks to improve patient outcomes
through enhanced clinical and research collaboration across the disciplines of oncology and …

Opinion statement Treatment-related cardiotoxicity remains a significant concern for breast
cancer patients undergoing cancer treatment and extends into the survivorship period, with …

Cardiovascular disease (CVD) and breast cancer cause substantial morbidity and mortality
in women and are major public health concerns. Breast cancer survivors are at a greater risk …

Background Cardiotoxicity is the most significant adverse event associated with trastuzumab
(T), the main component of HER2-positive breast cancer (BC) treatment. Less is known …

Summary At the 2018 ASCO Annual Meeting, data from several interesting studies in HER2-
positive metastatic breast cancer were presented. While not immediately practice changing …

Gastrointestinal (GI) tumors account for a quarter of all the cancer burden and a third of the
global cancer-related mortality. Among them, some cancers retain a dismal prognosis; …

In this article, we discuss the most recent literature for the management of asymptomatic left
ventricular dysfunction and heart failure related to chemotherapy, from prevention to the use …

Christine Cambareri, PharmD, BCPS, BCOP, CSP, and Laura Nolte, CRNP, MSN, OCN,
both of Abramson Cancer Center at the Hospital of the University of Pennsylvania, discuss …